
### [NCIT:C3363](http://purl.obolibrary.org/obo/NCIT_C3363)
**Label:** Sebaceous Gland Neoplasm

**Subclasses:** [NCIT:C8409](http://purl.obolibrary.org/obo/NCIT_C8409) (Malignant Sebaceous Neoplasm), [NCIT:C40310](http://purl.obolibrary.org/obo/NCIT_C40310) (Sebaceous Carcinoma), [NCIT:C134831](http://purl.obolibrary.org/obo/NCIT_C134831) (Eyelid Sebaceous Gland Carcinoma), [NCIT:C8525](http://purl.obolibrary.org/obo/NCIT_C8525) (Benign Sebaceous Neoplasm), [NCIT:C43340](http://purl.obolibrary.org/obo/NCIT_C43340) (Ocular Sebaceous Carcinoma), [NCIT:C43341](http://purl.obolibrary.org/obo/NCIT_C43341) (Extraocular Cutaneous Sebaceous Carcinoma), [NCIT:C40309](http://purl.obolibrary.org/obo/NCIT_C40309) (Vulvar Sebaceous Carcinoma), [NCIT:C43336](http://purl.obolibrary.org/obo/NCIT_C43336) (Sebaceoma), [NCIT:C40369](http://purl.obolibrary.org/obo/NCIT_C40369) (Sebaceous Breast Carcinoma), [NCIT:C4174](http://purl.obolibrary.org/obo/NCIT_C4174) (Sebaceous Adenoma), 

**Class expressions from DL-Learner:**

- [CL:2000021](http://purl.obolibrary.org/obo/CL_2000021) (sebaceous gland native cell) 62.50%
- [CL:0000317](http://purl.obolibrary.org/obo/CL_0000317) (sebum secreting cell) 62.50%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and [CL:2000021](http://purl.obolibrary.org/obo/CL_2000021) (sebaceous gland native cell) 62.50%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([CL:0002064](http://purl.obolibrary.org/obo/CL_0002064) (pancreatic acinar cell))) 62.50%
- Thing 51.30%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36116](http://purl.obolibrary.org/obo/NCIT_C36116) (Borderline Lesion))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36113](http://purl.obolibrary.org/obo/NCIT_C36113) (Anaplastic Lesion))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36109](http://purl.obolibrary.org/obo/NCIT_C36109) (Superficial Lesion))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36108](http://purl.obolibrary.org/obo/NCIT_C36108) (Encapsulated Mass))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36107](http://purl.obolibrary.org/obo/NCIT_C36107) (Hereditary Female Breast Carcinoma))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36106](http://purl.obolibrary.org/obo/NCIT_C36106) (Hereditary Male Breast Carcinoma))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36105](http://purl.obolibrary.org/obo/NCIT_C36105) (Indolent Clinical Course))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36104](http://purl.obolibrary.org/obo/NCIT_C36104) (Aggressive Clinical Course))) 47.86%
- [CL:0000152](http://purl.obolibrary.org/obo/CL_0000152) (exocrine cell) and (not ([NCIT:C36103](http://purl.obolibrary.org/obo/NCIT_C36103) (Rapidly Enlarging Mass))) 47.86%


